Life Sciences Transactions

Life sciences companies trust us to handle their most important matters – and we consistently deliver successful outcomes across the full spectrum of life sciences transactions. We leverage our decades of experience, deep industry knowledge, and culture of innovation and collaboration to deliver best-in-class legal advice on every matter.

• Broad-based Capital Markets Offering: From startups to public offerings, our highly skilled Capital Markets team provides strategic counsel on nearly every type of capital markets offering and under the laws of multiple jurisdictions. We represent issuers, underwriters, and other financial institutions in domestic and international equity and debt capital-raising transactions; establishment of U.S. and international securities exchange listings; and compliance with securities laws, securities exchange rules, and the corporate governance requirements.
• Venture Capital & Emerging Growth Companies: We advise emerging growth companies with all aspects of their business activities from formation, initial start-up advice to exit transactions, as well as the investors who help power innovation into new markets and access to new technologies and opportunities.
• Sophisticated M&A Deal Experience: Our sophisticated M&A lawyers understand the complex M&A issues that are most critical to change of control transactions involving life sciences companies and are adept at devising innovative ways to get deals done on time and on budget.
• Corporate Governance: We counsel life sciences management teams and boards of directors at all stages of growth. Our team includes several alumni of the SEC, bringing invaluable perspective and insight when guiding clients through the regulatory requirements of the federal securities laws as well as Nasdaq and NYSE listing standards.
• IP Experience: Our team of seasoned IP attorneys combines scientific expertise with legal acumen to help our clients protect, commercialize, and maximize the value of their innovations. We offer comprehensive IP services. Including IP due diligence in M&A.

Accolades and Recognitions:

• Chambers USA 2024 – Nationwide: Life Sciences
• Legal 500 2024 – U.S. Healthcare: Life Sciences
• Law360 – Life Sciences Practice Group of the Year
• Law360 – “MVPs” in Life Sciences
• LMG Life Sciences 2024 – Named General Patent Litigation Firm of the Year and shortlisted for six other awards
• LMG Life Sciences 2022 – Received four awards
   

---

“The team is known as an international firm with a strong U.S. footprint and sector expertise in life sciences and frequently called upon for strategically significant cross-border transactions." 

Chambers USA

---

Our attorneys have served as legal counsel in the following transactions:

• Goldman Sachs & Co. LLC and JP Morgan as underwriters in over $1.5 billion of equity offerings by Sarepta Therapeutics, Inc.
• Karuna Therapeutics, Inc. in its IPO and follow-on offerings, aggregating over $1.5 billion in proceeds
• SD Biosensor and SJL Partners in their $1.5 billion acquisition of Meridian Bioscience, Inc.
• Ipsen in its cross-border acquisition of Clementia Pharmaceuticals for up to $1.3 billion in upfront cash and CVRs
• Forma Therapeutics in its $1.1 billion sale to Novo Nordisk
• Viking Therapeuticsin its $550 million IPO and $633 million follow-on public offering
• Goldman Sachs & Co. LLC and other underwriters in the IPO and follow-on offerings by Arvinas, Inc., aggregating over $600 million in proceeds
• Kyverna Therapeutics, Inc. in its $367 million IPO
• Goldman Sachs & Co. LLC and other underwriters in the $140 million follow-on public offering by Syndax Pharmaceuticals, Inc.
• J.P. Morgan and other underwriters in Lexeo Therapeutics’ $100 million IPO and its $95 million private placement
• J.P. Morgan and the other underwriters in connection with CAMP4 Therapeutics Corporation's $75 million IPO